Text full multimedia monochrome

First time here?

Find out more about how The Lecture List works.

Do you organise talks?

Register to tell us about them. The Lecture List is a great place to be listed, but it's also an easy place to upload your information to. It's very simple and costs nothing. Find out more

Help!

Find out what you can do to keep The Lecture List online

Cloning, stem cells and regenerative medicine

This lecture will illustrate the potential value of using stem cells to study the cause of inherited diseases.


Extraordinary opportunities to study the molecular mechanisms that cause inherited diseases are being provided by new methods of producing stem cells. In principle many inherited diseases may be studied in this way including Motor Neuron Disease, schizophrenia, some forms of cancer and causes of sudden heart failure. In addition, human cells in the laboratory may provide important new approaches to the safety testing of new drugs. The lecture will illustrate not only the potential value of these new methods, but also the manner in which their development was prompted by research to clone a sheep.


Speaker(s):

Professor Sir Ian Wilmut FRS | talks | www

 

Date and Time:

19 October 2010 at 6:30 pm

Duration:

1 hour

 

Venue:

The Royal Society
6-9 Carlton House Terrace
London
SW1Y 5AG
+44 20 74 51 2500
http://www.royalsociety.org

More at The Royal Society...

 

Tickets:

Free

Available from:

Admission free – no ticket or advance booking required. Doors will open at 5.45pm and seats will be allocated on a first-come-first-served basis.

Additional Information:

This event will be broadcast live on the web at www.royalsociety.org/live

Visit our video archive at www.royalsociety.tv

For details of other public lectures and events this year please see our website www.royalsociety.org/events-diary

Register to tell a friend about this lecture.

Comments

If you would like to comment about this lecture, please register here.



 

Any ad revenue is entirely reinvested into the Lecture List's operating fund